Newsroom
Sorted by: Latest
-
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that results from a Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in advanced clear cell renal cell carcinoma (ccRCC) were accepted for a proffered paper oral presentation at the European Society of Medical Oncology (ESMO) Congress 2026, to be held October 23-...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Equity Income UCITS ETF 16.07.2026 GINC LN IE00BD842Y21 930,270.00 USD 60,755,990.19 65.310 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Equity Income UCITS ETF 16.07.2026 FGBL.LN IE00BYTH6121 617,840.00 USD 61,705,213.13 99.872 ...
-
GZA Congratulates Maine Maritime Academy on Welcoming NSMV State of Maine to Revamped Pier
CASTINE, Maine & SOUTH PORTLAND, Maine--(BUSINESS WIRE)--GZA GeoEnvironmental Inc. (GZA) congratulates its client Maine Maritime Academy on successfully opening phase 1 of MMA's revamped waterfront facility....
-
ParkOhio Announces Quarterly Dividend
CLEVELAND, OHIO--(BUSINESS WIRE)--The Board of Directors of Park-Ohio Holdings Corp. (NASDAQ: PKOH) has declared a quarterly cash dividend of $0.125 per share on the common stock outstanding, to be paid on August 14, 2026, to shareholders of record as of the close of business on July 31, 2026. ParkOhio is a diversified international company providing world-class customers with a supply chain management outsourcing service, capital equipment used on their production lines, and manufactured compo...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust United Kingdom AlphaDEX UCITS ETF 16.07.2026 FKUD IE00BD9N0445 121,463.00 GBP 3,687,767.07 30.361 ...
-
The Trade Desk Appoints Ron Lamprecht as Chief Business Development Officer, Senior Vice President
VENTURA, Calif.--(BUSINESS WIRE)--The Trade Desk, a leading global advertising technology company, today announced the appointment of Ron Lamprecht as Chief Business Development Officer and Senior Vice President. In this newly created role, Lamprecht will build strategic partnerships that expand our market opportunity, develop new commercial models and enterprise-wide global opportunities. He will report to Chief Operating Officer Vivek Kundra and be based in New York City. Lamprecht brings mor...
-
University of Texas Athletics and ShopBack Launch Year-Round Shopping Rewards Platform for Longhorns Fans
AUSTIN, Texas--(BUSINESS WIRE)--Texas Athletics and ShopBack announced a new relationship that names the company the Official Shopping Rewards Sponsor of the Texas Longhorns....
-
Qualcomm Announces Quarterly Cash Dividend
SAN DIEGO--(BUSINESS WIRE)--Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.92 per common share, payable on September 24, 2026, to stockholders of record at the close of business on September 3, 2026.About QualcommQualcomm is a global computing leader at the center of the AI era, enabling intelligence to scale from the most personal devices to large-scale infrastructure. Building on more than four decades of innovation, we develop platforms and solutions that...
-
ME Therapeutics Closes Over-Subscribed Private Placement
VANCOUVER, British Columbia--(BUSINESS WIRE)--ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has closed its previously announced non-brokered private placement for aggregate proceeds of $576,500.60 (the “Financing”). Closing of the Financing The Financing consisted of the issuance of 33...